Anaemia causes morbidity and mortality in cancer patients with negative impact on treatment outcome and prognosis. It has been a common practice to offer blood transfusion which comes with its own disadvantages. Therefore, alternative strategies are required to obviate the recurrent need for blood transfusion.
Work up of Patient
Currently, the best treatment decisions for anaemia might be based on measurements of serum ferritin (SF), transferrin saturation (TSAT), soluble transferrin receptor (sTfR), ferritin index (FI = sTfR/log SF), hypochromic reticulocytes (CHR) and C-reactive protein (CRP).
Parenteral iron therapy has advantages over oral route as compliance is the limiting factor in oral iron therapy and gastro-intestinal side effects are increased by oral route. A patient’s total body iron deficit can be calculated using the Ganzoni formula. Options for use of parenteral iron are iron dextran, iron sucrose and ferric gluconate.
There are numerous trials which evaluate parenteral iron in cancer patients, but only a few evaluate them in gynaecologic malignancies. These trials conclude that usage leads to decreased transfusion rate and slow, steady and sustained rise in Hb level.
Certain recommendations include safe and effective use of parenteral iron. Lowest Hb level for injectable iron should be 10 gm/dl. Post-surgical patients should be haemodynamically stable. Preparations can be given according to individual availability, cost and feasibility.
Parenteral iron therapies improve time to target haemoglobin levels. They decrease need of blood transfusion. We recommend the use of intravenous iron therapy under supervision wherever feasible.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Barrett-Lee P, Bokemeyer C, Gascon P, Nortier JW, Schneider M, Schrijvers D, et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist. 2005;10:743–57.
Birgegard G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Eur J Haematol. 2006;77:378–86.
Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology. 1996;201:553–8.
Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr, et al. Pretreatment hemoglobin level influences local control and survival of T1–T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol. 1995;13:2077–83.
Glaser CM, Millesi W, Kornek GV, Lang S, Schüll B, Watzinger F, Selzer E, Lavey RS. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys. 2001;50(3):705–15.
Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–74.
Achariyapota V, Benjapibal M, Chaopotong P. Prevalence and incidence of anemia in Thai patients with gynecologic cancer. Asian Pac J Cancer Prev. 2010;1(11):1229–33.
Grotto HZ. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol. 2008;25:12–21.
Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100:2303–20.
Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey [ECAS]: a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293–306.
Melosky BL. Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer. Curr Oncol. 2008;15:S10–5.
Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–23.
Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol. 1999;70:7–12.
Ganz T. Molecular control of iron transport. J Am Soc Nephrol. 2007;18:394–400.
Adamson JW. The anemia of inflammation/malignancy: mechanisms and management. Hematol Am Soc Hematol Educ Progr. 2008;2008:159–65.
Price E, Schrier S. Unexplained aspects of anemia of inflammation. Adv Hematol. 2010;2010:508739.
McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, Mudaly M, Richardson C, Barlow D, Bomford A, Peters TJ, Raja KB, Shirali S, Hediger MA, Farzaneh F, Simpson RJ. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science. 2001;291(5509):1755–9.
Muir A, Hopfer U. Regional specificity of iron uptake by smal intestinal brush-boarder membranes from normal and iron deficient mice. Gastrointest Liver Pathol. 1985;11:6376–9.
Brittenham GM. Disorders of iron metabolism: iron deficiency and iron overload. In: Hoffman R, editor. Hematology: basic principles and practice. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013. p. 437–49.
Garg A, Agarwal M, Shankar U, Shetty S. Comparative study of oral iron and intravenous iron sucrose for the treatment of iron deficiency anemia in pregnancy. Int J Reprod Contracept Obstet Gynecol. 2017;6:172–5.
Thomas G. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol. 2001;28:60–5.
Henry DH. Parenteral iron therapy in cancer-associated anemia . Hematol Am Soc Hematol Edu Progr Haematol. 2010;2010:351–6.
Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey [ECAS]: a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293–306.
Mitchell D. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Milan, Italy: ESMO; 2010.
Steinmetz HT. The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol. 2012;3:177–91.
Mikhael J, Melosky B, Cripps C, Rayson D, Kouroukis CT. Canadian supportive care recommendations for the management of anemia in patients with cancer. Curr Oncol. 2007;14:209–17.
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28:4996–5010.
NCCN  Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia. Available at: http://www.nccn.org/professionals/ physician_gls/pdf/anemia.pdf
Kruske SG, Ruben AR, Brewster DR. An iron treatment trial in an aboriginal community: improving non-adherence. J Paediatr Child Health. 1999;35:153.
Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0117383.
Auerbach M, Liang AS, Glaspy J. Intravenous iron in chemotherapy and cancer-related anemia. Community Oncol. 2012;9:289.
Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—systematic review and meta-analysis of randomised controlled trials. Acta Oncol. 2013;52:18.
Auerbach M, Chaudhry M, Goldman H, Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med. 1998;131:257.
Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr. 1970;100:301–3.
Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, Dhaens G, Gasche C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT®) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182–92.
Kitsati N, Liakos D, Ermeidi E, et al. Rapid elevation of transferrin saturation and serum hepcidin concentration in hemodialysis patients after intravenous iron infusion. Haematologica. 2015;100:e80.
Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105:199–204.
Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynaecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010;116:522–5.
Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol. 2013;131:679–82.
Dreyer G, Mostert A, Visser C, et al. The severity and optimal management of iron deficiency and anaemia before radiation for cervical cancer at the University of Pretoria Academic Hospitals. South Afr J Gynaecol Oncol. 2017;9(1):11–5.
The authors declare no funding was obtained.
Conflict of interest
The authors declare that they have no conflict of interest.
All above-mentioned authors gave final approval for publication. All above-mentioned authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Corresponding author Amit Choraria takes full responsibility for the work as a whole, including the study design, access to data and the decision to submit and publish the manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Choraria, A., Tiwari, A. & Mittal, S. Role of Parenteral Iron Therapy in Gynaecologic Malignancies: A Review of Literature and Recommendations for Practice in a Cancer Centre in a Developing Country. Indian J Gynecol Oncolog 19, 23 (2021). https://doi.org/10.1007/s40944-021-00504-0
- Parenteral iron
- Gynaecologic malignancies
- Injectable iron
- Intravenous iron